Partner Headlines - GSK

  1. UPDATE: GlaxoSmithKline Says Tianjin Explosion Strained Supply ...

    Benzinga
  2. GlasxoSmithKlien Says It Holds Sales Rights To Tenozet In Japan/China ...

    Benzinga
  3. Five Prime Therapeutics Announces Oral Presentation of Initial ...

    Benzinga
  4. Dodge & Cox Acquires Stake in Priceline

    GuruFocus
  5. AptarGroup: The Leader in Dispensing Innovation

    GuruFocus
  6. US Stock Futures Slide Ahead Of Deere, Foot Locker Earnings

    Benzinga
  7. Novartis Acquires Rremaining Rghts to GSK's Ofatumumab to Develop ...

    Benzinga
  8. GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment ...

    GuruFocus
  9. Gilead Q2 Earnings Soar As HCV Shines, HIV Rebounds

    IBD
  10. Week Ahead: FOMC Meeting, GDP and More Earnings

    FoxBusiness
  11. Novartis' Mixed Q2: Sandoz Booms, Alcon Struggles

    IBD
  12. It's Not Too Late To Buy Gilead Sciences

    GuruFocus
  13. Benzinga's Volume Movers

    Benzinga
  14. Can Hepatitis B Be A Blockbuster Bug?

    IBD
  15. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD
  16. Biotech IPOs Steam Ahead Despite Fears Of Overload

    IBD
  17. 5 NYSE Healthcare Stocks With The Highest ROE

    Benzinga
  18. Jim Cramer Advises His Viewers On GlaxoSmithKline, American International ...

    Benzinga
  19. Billionaire George Soros Ups Two Stakes in First Quarter

    GuruFocus
  20. Weekly 3-Year Low Highlights: GSK, TRP, NOV, CHK

    GuruFocus
  21. Guru Stocks at 52-Week Lows: XOM, WMT, PG, CVX, GSK

    GuruFocus
  22. Axovant IPO Best In 20 Years

    IBD
  23. Axovant Sciences Sets 20-Year Record For Biotech IPOs

    IBD
  24. Isis, Biogen Rare-Disease Drug Aids Infant Survival

    IBD
  25. Will GlaxoSmithKline Cut Its 6% Dividend?

    GuruFocus
  26. Perrigo buys Glaxo OTC drugs

    IBD
  27. Will Perrigo's Glaxo Buy Make It Too Pricey?

    IBD
  28. Big Pharma Companies Are Betting On Regenerative Medicine - Should ...

    GuruFocus
  29. Analyst Says GlaxoSmithKline Acquisition Will Benefit Pfizer

    GuruFocus
  30. 9 International Dividend Dogs With Upside Potential

    GuruFocus
  31. Endo International Acquires Par Pharmaceuticals For $8 Billion

    GuruFocus
  32. Tweedy Browne's Stocks With High Growing Yield

    GuruFocus
  33. Kahn Brothers Ups Investment in 4 Stocks

    GuruFocus
  34. Glaxo more bullish than Q1

    IBD
  35. IPO Stock Watch: Adaptimmune Upsizes But Stock Slips

    IBD
  36. Glaxo Q1 Earnings Miss, But 5-Year Guidance Strong

    IBD
  37. Isis Pharma Up As Bayer Licenses Thrombosis Drug

    IBD
  38. GlaxoSmithKline

    IBD
  39. Novartis EPS beats the Street

    IBD
  40. Taking a Closer Look at GlaxoSmithKline

    GuruFocus
  41. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative ...

    Benzinga
  42. New Potential HIV Vaccine Drug 'Absolutely 100% Effective' In ...

    Benzinga
  43. Dodge & Cox 2014 Equity Year in Review

    GuruFocus
  44. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  45. Making Money With Charles Payne: 02/13/15

    FoxBusiness
  46. Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, ...

    Benzinga
  47. Stocks Edge Higher Friday; Glaxo, Taiwan Semi Muscle Up

    IBD
  48. Bestinfond's Top 5 New Buys During Q4

    GuruFocus
  49. Mylan Makes Deals In Women's Health, Lung Disease

    IBD
  50. Can GlaxoSmithKline Continue Striving in the Face of World Challenges? ...

    GuruFocus
  51. GlaxoSmithKline Expands Its Portfolio Of Medicines In The US ...

    Benzinga
  52. Benzinga's Weekend M&A Chatter

    Benzinga
  53. Gilead Sciences Still has More Upside

    GuruFocus
  54. Johnson & Johnson Riding High On Ebola Vaccines

    GuruFocus
  55. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  56. Hot Biotech Stocks: Isis, Kite Jump On Big Deals

    IBD
  57. Isis Pharma To Develop GI Drugs With J&J

    IBD
  58. Pfizer, Home of Lipitor and Viagra, Lifts Dividend

    IBD
  59. Ebola Drug Work Continues

    IBD
  60. Viral Investing: Ebola Drug Makers' Varied Strategies

    IBD
  61. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD
  62. Weekly 3-Year Low Highlights: RDS.B, GSK, WPZ, CLR

    GuruFocus
  63. Market Mixed Amid Plan To Spend $300 Million On Ebola Vaccines

    Benzinga
  64. Pfizer Spreading Its Wings Into A New Domain Of Life Sciences

    GuruFocus
  65. Merck Bets $9.5 Billion On Cubist's War On Superbugs

    IBD
  66. GlaxoSmithKline's Move A Testament That Pharma Companies Are ...

    Benzinga
  67. The Top 5 European Stocks Held During Q3

    GuruFocus
  68. BioMarin buying Prosensa

    IBD
  69. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  70. Screening Pharma Stocks Amid Turnaround

    YCharts
  71. Jeff Auxier Buys Berkshire Hathaway in Third Quarter

    GuruFocus
  72. Apollo may make Glaxo offer

    IBD
  73. Irving Kahn Starts New Position In GlaxoSmithKline

    GuruFocus
  74. Irving Kahn Buys Stake in GlaxoSmithKline During Q3 2014

    GuruFocus
  75. Insys Q3 Beats Estimates, Helping Stock Rebound

    IBD
  76. Kahn Brothers' Third Quarter Numbers

    GuruFocus
  77. Ebola Vaccine Contenders

    Benzinga
  78. Stock Futures Upshift On Data; Yahoo, Broadcom, Boeing Climb

    IBD
  79. Benzinga Weekly Preview: Earnings Season Is In Full Swing

    Benzinga
  80. Diamond Hill Capital Comments on GlaxoSmithKline PLC

    GuruFocus
  81. Sarepta Therapeutics Shares Up On Ebola Drug Safety Study

    Benzinga
  82. Hazmat Suit Maker Lakeland Soars On Dallas Ebola Fear

    IBD
  83. Ebola-Related Pharma Stocks Soar On First U.S. Case

    IBD
  84. Action Heats Up in Ebola-Related Equities

    FoxBusiness
  85. Guru Stocks at 52-Week Lows: BHP, GSK, UTX, SAP, TEF

    GuruFocus
  86. Pharma Stocks: Surprising Shift In U.S. Drug Market

    YCharts
  87. Royal Bank of Scotland

    IBD
  88. Gilead's New HIV Drug Key To Long-Term Strategy

    IBD
  89. International Securities For A Diversified Income Portfolio

    GuruFocus
  90. Could European Funds Offer An Opportunity Now?

    Benzinga
  91. Widely Held Guru Stocks Trading In Europe

    GuruFocus
  92. 3 Partnerships Pushing The Pharmaceutical Sector Forward

    Benzinga
  93. Guru Stocks at 52-Week Lows: BHP, GSK, EC, VALE, ABB

    GuruFocus
  94. China Fines Glaxo For Bribes

    IBD
  95. Guru Stocks at 52-Week Lows: BHP, GSK, VOD, LYG, TEF

    GuruFocus
  96. Stock Futures Down, But Not Far; Alibaba Sets IPO Price Range

    IBD
  97. Benzinga's M&A Chatter for Wednesday August 27, 2014

    Benzinga
  98. GSK Receives FDA Approval Of An Additional Promacta (eltrombopag) ...

    Benzinga
  99. InterMune Stock Spikes On Rare Big Biotech Buyout

    IBD
  100. 3 Dividend Kings From The U.K. I Love To Buy

    GuruFocus
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!